Mexico HIV Drugs Market Analysis Report 2022 to 2030

Mexico HIV Drugs Market Analysis

$ 3999

Mexico HIV Drugs Market is at around $0.48 Bn in 2023 and is projected to reach $0.62 Bn in 2030, exhibiting a CAGR of 3.85% during the forecast period. Increasing HIV prevalence, government initiatives, and the expansion of healthcare infrastructure are propelling the market growth. The market is dominated by key players like Genomma Lab Internacional, Laboratories Chinoin, Gilead Sciences, ViiV Healthcare, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffman-La Roche Ltd.

ID: IN10MXPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Aneri Parekh

Buy Now

Mexico HIV Drugs Market Executive Summary

Mexico HIV Drugs Market is at around $0.48 Bn in 2023 and is projected to reach $0.62 Bn in 2030, exhibiting a CAGR of 3.85% during the forecast period.

The HIV Drugs Market in Mexico includes the manufacture, distribution, sales, and consumption of antiretroviral drugs, as well as other therapies and medications targeted at slowing the course of the virus and improving patients' quality of life. Government regulations, healthcare infrastructure, prevalence rates, and availability of cheap treatment alternatives all have an impact on the market, influencing both domestic and international pharmaceutical businesses operating in Mexico.

The Mexican HIV medications industry is expanding steadily, owing to increased knowledge, improved access to healthcare, and government initiatives. To meet the increased demand for antiretroviral treatments, key players are expanding their product ranges and strengthening distribution networks. However, the sector has obstacles such as pricing pressures and regulatory barriers.

The global HIV drug sector has expanded quickly, with a value estimated at $31.7 Bn in 2023. Rising HIV diagnosis rates, combined with government efforts to increase HIV management abilities, have boosted the HIV drug industry. The market situation is changing as generic competition grows. Financial hurdles must be removed, stigma reduced, and access to therapy expanded in developing nations to proceed.

Genomma Lab is a key player in the Mexican HIV drug industry, offering a range of generic antiretroviral treatments. Chesco, Cidofovir, Combivent, Efavirenz, Kaletra, Lamivudine, Lopinavir, Ritonavir, and Stavudine are the brands under which the firm sells HIV medications. The company's products are offered in more than 30 countries worldwide.

Mexico HIV drugs market

Market Dynamics

Market Growth Drivers:

Increasing HIV Prevalence: The increased HIV prevalence increases demand for HIV pharmaceuticals, notably antiretroviral therapy (ART) medications.

Government Initiatives: The Mexican government has implemented several anti-HIV/ AIDS efforts, including boosting access to healthcare services and subsidizing HIV medications. The market's growth is driven by government support through funding and HIV/ AIDS policies.

Expansion of Healthcare Infrastructure: Improving healthcare infrastructure, particularly in rural and underserved areas, allows for better access to HIV diagnosis and treatment. Increased accessibility encourages more people to seek HIV treatment, driving up demand for HIV medications.

Market Restraints:

Stigma and Discrimination: The stigma associated with HIV/ AIDS may dissuade people from getting tested and treated. Fear of discrimination or social ostracization may delay diagnosis and therapy commencement.

Affordability: The cost of HIV drugs may be prohibitive for many people, particularly those without appropriate insurance or financial resources. This could lead to treatment non-adherence or incomplete treatment regimens.

Supply Chain Challenges: Disruptions in the supply chain, such as challenges with drug manufacturing, delivery, and procurement, may result in HIV medicine shortages or interruptions.

Healthcare Policies and Regulatory Landscape

The Mexican Secretariat of Health (Secretaría de Salud) oversees pharmaceutical and medical device laws, as well as national health policy. The Sanitary Authorization Commission (CAS), which has jurisdiction over pharmaceutical sanitary registration in Mexico, collaborates with the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) to manage the process. The Center for Integrated Services (CIS) handles requests and technical meetings for COFEPRIS' New Molecule Committee. The Mexican government places a great value on affordable healthcare and rigorously controls drug costs. This can be a substantial obstacle to breakthrough, expensive treatments, making it difficult for companies to recoup their initial investment.

Competitive Landscape

Key Players:

Genomma Lab Internacional
Laboratories Chinoin
Gilead Sciences
ViiV Healthcare
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.
F. Hoffman-La Roche Ltd.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.